1. Home
  2. RFIL vs ACOG Comparison

RFIL vs ACOG Comparison

Compare RFIL & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RF Industries Ltd.

RFIL

RF Industries Ltd.

HOLD

Current Price

$7.99

Market Cap

191.3M

Sector

Technology

ML Signal

HOLD

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$8.84

Market Cap

193.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
RFIL
ACOG
Founded
1979
2000
Country
United States
Canada
Employees
N/A
N/A
Industry
Electrical Products
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
191.3M
193.6M
IPO Year
1996
2024

Fundamental Metrics

Financial Performance
Metric
RFIL
ACOG
Price
$7.99
$8.84
Analyst Decision
Hold
Strong Buy
Analyst Count
1
2
Target Price
$11.25
$16.00
AVG Volume (30 Days)
240.0K
126.6K
Earning Date
06-15-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
101.59
41.58
EPS
0.20
N/A
Revenue
$55,325,000.00
$10,220,275.00
Revenue This Year
$9.65
$139.22
Revenue Next Year
$6.40
$134.48
P/E Ratio
$40.20
N/A
Revenue Growth
10.22
N/A
52 Week Low
$5.54
$4.50
52 Week High
$22.30
$10.14

Technical Indicators

Market Signals
Indicator
RFIL
ACOG
Relative Strength Index (RSI) 23.16 47.35
Support Level $5.58 $7.50
Resistance Level $13.59 $9.04
Average True Range (ATR) 0.62 0.51
MACD -0.14 -0.10
Stochastic Oscillator 4.49 34.48

Price Performance

Historical Comparison
RFIL
ACOG

About RFIL RF Industries Ltd.

RF Industries Ltd is engaged in the design, manufacture, and marketing of interconnect products and systems, including coaxial and specialty cables, fiber optic cables and connectors, and electrical and electronic specialty cables. The company has one operating segment. The company operates in Canada, Germany, China, the USA, and the United Kingdom, and Others.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: